Published in Oncogene on July 17, 2003
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83
Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol Cell Biol (2006) 1.08
Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol Cell Biol (2005) 1.05
The proline-rich domain in p63 is necessary for the transcriptional and apoptosis-inducing activities of TAp63. Oncogene (2007) 0.86
Targeting the p53 pathway. Surg Oncol Clin N Am (2013) 0.82
N-terminal proline-rich domain is required for scrambling activity of human phospholipid scramblases. J Biol Chem (2014) 0.78
The Trp53 delta proline (Trp53ΔP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development. Mol Carcinog (2015) 0.75
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers. Cancer Inform (2017) 0.75
The proline rich domain of p53 is dispensable for MGMT-dependent DNA repair and cell survival following alkylation damage. Cell Death Differ (2017) 0.75
VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell (2012) 2.14
Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett (2004) 2.13
A PANorama of PAX genes in cancer and development. Nat Rev Cancer (2006) 2.01
Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene (2003) 1.99
Disruption of ROBO2 is associated with urinary tract anomalies and confers risk of vesicoureteral reflux. Am J Hum Genet (2007) 1.85
YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J (2013) 1.38
A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One (2009) 1.21
Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol Cancer Ther (2005) 1.15
Y-box factor YB1 controls p53 apoptotic function. Oncogene (2005) 1.08
Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. Blood (2011) 1.05
Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res (2006) 1.05
YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst (2011) 1.04
Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins. J Cell Biol (2009) 1.01
The dynamin inhibitors MiTMAB and OcTMAB induce cytokinesis failure and inhibit cell proliferation in human cancer cells. Mol Cancer Ther (2010) 1.01
Nuclear localization of Y-box factor YB1 requires wild-type p53. Oncogene (2003) 1.01
PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Res (2008) 0.98
The Wnt receptor Ryk plays a role in mammalian planar cell polarity signaling. J Biol Chem (2012) 0.98
The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem (2003) 0.98
PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. Melanoma Res (2011) 0.97
The mesenchymal architecture of the cranial mesoderm of mouse embryos is disrupted by the loss of Twist1 function. Dev Biol (2012) 0.97
A novel Cys1638Tyr NC1 domain substitution in alpha5(IV) collagen causes Alport syndrome with late onset renal failure without hearing loss or eye abnormalities. Nephrol Dial Transplant (2007) 0.93
Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol (2002) 0.92
A rapid and optimization-free procedure allows the in vivo detection of subtle cell cycle and ploidy alterations in tissues by flow cytometry. Cell Cycle (2010) 0.89
Delivery of antisense peptide nucleic acids (PNAs) to the cytosol by disulphide conjugation to a lipophilic cation. FEBS Lett (2004) 0.89
PAX3 Is extensively expressed in benign and malignant tissues of the melanocytic lineage in humans. J Invest Dermatol (2010) 0.89
The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One (2011) 0.88
Cohesin is required for activation of MYC by estradiol. PLoS One (2012) 0.87
Does Δ133p53 isoform trigger inflammation and autoimmunity? Cell Cycle (2012) 0.87
Enhanced isolation of fibroblasts from human skin explants. Biotechniques (2012) 0.86
Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet (2006) 0.85
PAX Genes in Cancer; Friends or Foes? Front Genet (2012) 0.85
Prognostic association of YB-1 expression in breast cancers: a matter of antibody. PLoS One (2011) 0.83
Dynamin inhibitors induce caspase-mediated apoptosis following cytokinesis failure in human cancer cells and this is blocked by Bcl-2 overexpression. Mol Cancer (2011) 0.82
Self-regulated Pax gene expression and modulation by the TGFbeta superfamily. Crit Rev Biochem Mol Biol (2008) 0.81
Somatic reactivation of expression of the silent maternal Mest allele and acquisition of normal reproductive behaviour in a colony of Peg1/Mest mutant mice. J Reprod Dev (2012) 0.80
Accelerated decline in lung function in cigarette smokers is associated with TP53/MDM2 polymorphisms. Hum Genet (2009) 0.80
Targeted therapy; from advanced melanoma to the adjuvant setting. Front Oncol (2013) 0.79
Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21(WAF1/CIP1). J Cell Sci (2009) 0.78
Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus. Nephrology (Carlton) (2012) 0.77
Increased paired box transcription factor 8 has a survival function in glioma. BMC Cancer (2014) 0.77
Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cells. Virus Res (2009) 0.76
Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1. BMC Genomics (2003) 0.75
Heterogeneous gene expression changes in colorectal cancer cells share the WNT pathway in response to growth suppression by APHS-mediated COX-2 inhibition. Biologics (2008) 0.75
The deleted in colorectal carcinoma (DCC) gene 201 R --> G polymorphism: no evidence for genetic association with autoimmune disease. Eur J Hum Genet (2003) 0.75
Erratum: A cross comparison of technologies for the detection of microRNAs in clinical FFPE samples of hepatoblastoma patients. Sci Rep (2015) 0.75
Embryonal hyperplasia of Bowman's capsular epithelium in patients with WT1 mutations. Pediatr Nephrol (2002) 0.75